Bortezomib in the Treatment of Acquired von Willebrand Disease Secondary to Monoclonal Gammopathy of Undetermined Significance

Autores/as

  • Kenneth Byrd University of Kansas School of Medicine - Wichita
  • Phu Truong

DOI:

https://doi.org/10.17161/kjm.v7i4.11507

Palabras clave:

von Willebrand diseases, bortezomib, monoclonal gammopathy of undetermined significance

Métricas

File downloads
338
Jan 2015Jul 2015Jan 2016Jul 2016Jan 2017Jul 2017Jan 2018Jul 2018Jan 2019Jul 2019Jan 2020Jul 2020Jan 2021Jul 2021Jan 2022Jul 2022Jan 2023Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 20268
|

Descargas

Publicado

2014-11-06

Número

Vol. 7 Núm. 4 (2014)

Sección

Case Reports

Licencia

All articles in the Kansas Journal of Medicine are licensed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND 4.0). 

 

Cómo citar

Byrd, K., & Truong, P. (2014). Bortezomib in the Treatment of Acquired von Willebrand Disease Secondary to Monoclonal Gammopathy of Undetermined Significance. Kansas Journal of Medicine, 7(4), 167-170. https://doi.org/10.17161/kjm.v7i4.11507